NASDAQ:AMLN - Amylin Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. Amylin maintains a research and early development program focused on peptide and protein therapeutics. It has also entered into alliances and business initiatives, including its relationship with Biocon, Limited (Biocon) to develop pharmaceutical products, including AC165198, a peptide hybrid drug candidate for diabetes, which was developed from its phybrid technology platform. In August 2012, Bristol-Myers Squibb Company acquired the Company.

Receive AMLN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:AMLN
Previous Symbol
CUSIPN/A
Phone+1-858-5522200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Amylin Pharmaceuticals (NASDAQ:AMLN) Frequently Asked Questions

What is Amylin Pharmaceuticals' stock symbol?

Amylin Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMLN."

Has Amylin Pharmaceuticals been receiving favorable news coverage?

News articles about AMLN stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amylin Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Amylin Pharmaceuticals?

Shares of AMLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amylin Pharmaceuticals' official website?

The official website for Amylin Pharmaceuticals is http://www.amylin.com.

How can I contact Amylin Pharmaceuticals?

Amylin Pharmaceuticals' mailing address is 9360 Towne Centre Dr Ste 110, SAN DIEGO, CA 92121-3030, United States. The biopharmaceutical company can be reached via phone at +1-858-5522200.


MarketBeat Community Rating for Amylin Pharmaceuticals (NASDAQ AMLN)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Amylin Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel